ECYT Key Stats
- Merck Stock Is a Good Investment (According to Merck) May 24
- Merck Stock Is a Good Investment (According to Merck) Fool May 23
- ENDOCYTE INC Files SEC form 10-Q, Quarterly Report May 10
- Endocyte Appoints Scot L. Harper, Ph.D., as Vice President of Clinical Operation... May 7
- Wider-than-Expected Loss at Endocyte May 6
- Wider-than-Expected Loss at Endocyte - Analyst Blog Zacks May 6
- Why Royalty And Milestone Partnership Dynamics Imply Trovagene Could Triple May 3
- Endocyte's CEO Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 2
- Endocyte Reports First Quarter 2013 Financial Results and Business Update noodls May 2
- Endocyte, Inc. (ECYT) Posts Q1 Loss of 11c/Share Street Insider May 2
ECYT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Endocyte is up 123.2% over the last year vs S&P 500 Total Return up 27.77%, Lannett Company up 218.5%, and Merck up 30.48%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ECYT
Pro Report PDF for ECYT
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ECYT Pro Report PDF
Pro Strategies Featuring ECYT
Did Endocyte make it into our Pro Portfolio Strategies?